Krishna Institute of Medical Sciences financials: balance sheet, profit and loss, cash flow

NSE: KIMSBSE: 543308Healthcare ServicesSmall Cap

Krishna Institute of Medical Sciences Limited · Face value ₹2 · Listed Jun 2021 · Issue price ₹825

₹704.60₹6.95 (1.00%)BSE ₹704.80

Share price at the NSE close on 28 Oct 2026. Previous close ₹697.65.

28 Oct: open ₹693.00, high ₹709.60, low ₹689.10

52-week range of traded prices to 28 Oct 2026

₹575.80Low, 27 Jan 2026₹858.00High, 6 Jul 2026

Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar

Market cap: ₹29,594 Cr285th largest listed
P/E: 144.71
P/B: 13.17
Dividend yield: Nonein the last 12 months
ROE: 9.3%
ROCE: 8.7%
Debt to equity: 1.27
Volume, NSE: 4,45,11569.9% delivered

Krishna Institute of Medical Sciences' financial statements for the 6 years to Mar 2026, consolidated: the company and its subsidiaries together, with the twelve months to Jun 2026 after them.

6 years at a glance

₹ crore, years to March.Krishna Institute of Medical Sciences annual reports

Revenue, net profit and borrowings, ₹ crore

Revenue
Net profit
Borrowings

Peak revenue ₹3,905 Cr, year to Mar 2026; lowest ₹1,330 Cr, year to Mar 2021

Operating and net margin, per cent

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

Revenue3,905
Materials and goods−809
Employee costs−682
Other expenses−1,612
Operating profit802
Depreciation−283
Other income+26
One-off items−11
Finance costs−203
Profit before tax331
Tax−92
Joint ventures+2.6
Net profit242

What the company owns

Plant, investments and other assets₹7,018 Cr
Receivables₹554 Cr
Inventory₹97 Cr
Cash and bank₹75 Cr
Current investments₹15 Cr

What pays for it: net worth and liabilities

Borrowings₹3,244 Cr
Net worth₹2,559 Cr
Other liabilities₹1,633 Cr
Owed to suppliers₹323 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Krishna Institute of Medical Sciences quarterly results

₹ crore	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026Filed 15 May	Jun 2026Twelve monthsFiled 3 Aug
Revenue from operations	1,330	1,651	2,198	2,498	3,035	3,905	4,213
	959	1,135	1,594	1,858	2,252	3,103	3,380
Materials and goods bought	289	355	481	530	627	809	870
Employee costs	220	262	346	422	500	682	743
Other expenses	450	518	767	905	1,126	1,612	1,767
Operating profit before depreciation	371	516	604	640	783	802	833
Operating margin	27.9%	31.2%	27.5%	25.6%	25.8%	20.5%	19.8%
Materials, % of revenue	21.7%	21.5%	21.9%	21.2%	20.7%	20.7%	20.6%
Employee costs, % of revenue	16.6%	15.9%	15.8%	16.9%	16.5%	17.5%	17.6%
Other expenses, % of revenue	33.8%	31.4%	34.9%	36.2%	37.1%	41.3%	41.9%
Depreciation and amortisation	70	73	129	147	177	283	331
Operating profit after depreciation	301	443	475	494	606	519	502
Other income	10	20	26	13	32	26	36
Finance costs	32	16	31	47	90	203	253
Profit before one-off items and tax	279	447	470	460	547	343	284
One-off items	0	0	15	0	11	−11	−11
Profit before tax	279	447	485	460	558	331	273
	74	114	119	124	143	92	82
Current tax	78	114	117	120	150	136	139
Deferred tax	−4	0	2	4	−6	−44	−57
Share of profit of joint ventures and associates	–	10	–	0	–	3	4
	205	344	366	336	415	242	194
Belonging to the company's shareholders	201	333	336	310	385	241	205
Belonging to outside owners of subsidiaries	4	11	29	26	30	1	–
Other comprehensive income	0	0	1	0	−2	0	1
Total comprehensive income	205	344	367	336	413	242	195
Net margin	15.5%	20.8%	16.6%	13.5%	13.7%	6.2%	4.6%
Net margin without joint ventures and associates	–	20.2%	–	13.5%	–	6.1%	–

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ crore	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026Filed 15 May
	876	1,411	1,938	2,093	2,419	2,559
	864	1,387	1,670	1,828	2,138	2,247
Share capital	78	80	80	80	80	80
Reserves	786	1,307	1,590	1,748	2,058	2,167
Belonging to outside owners of subsidiaries	12	23	268	265	281	311
	240	161	678	1,355	2,557	3,244
Repayable after a year	185	138	634	1,226	2,287	2,673
Repayable within a year	55	23	45	129	270	571
	278	215	296	452	836	1,239
Trade payables	132	130	174	197	269	323
Other financial liabilities	49	24	30	61	216	234
Other liabilities	23	28	33	46	54	78
Provisions	10	10	14	19	26	33
Tax owed	9	0	0	0	2	0
	282	282	707	1,306	2,481	3,961
Other financial liabilities	1	89	0	6	78	1,175
Other liabilities	1	0	0	0	36	–
Provisions	16	17	24	27	34	46
Deferred tax	36	38	49	46	47	68
Trade payables	43	0	0	0	0	0
Total assets	1,436	1,907	2,941	3,852	5,736	7,759
	985	1,514	2,464	3,259	5,039	6,821
Plant in use, after depreciation	771	771	1,381	1,730	2,199	4,186
Plant being built	9	21	477	600	1,214	606
Intangible assets	25	150	78	65	811	57
Goodwill	85	85	308	308	339	339
Intangible assets being developed	0	0	0	331	0	0
Property held to earn rent	51	0	0	0	0	0
Investments	0	332	0	74	1	1
Stakes in joint ventures and associates	0	0	0	0	77	0
Loans given	16	0	0	26	6	13
Other financial assets	3	40	57	93	60	1,294
Deferred tax	3	21	64	32	104	127
Other assets	22	95	100	0	230	198
	451	393	478	593	697	937
Inventories	24	36	43	49	64	97
Trade receivables	110	129	253	294	395	554
Cash and cash equivalents	52	26	62	47	56	55
Other bank balances	232	164	5	2	24	19
Current investments	0	0	68	83	22	15
Loans given	2	0	0	0	48	72
Other financial assets	23	28	36	36	51	68
Tax paid in advance	0	0	0	46	0	0
Other assets	7	10	11	36	38	57
Net debt	−45	−29	544	1,223	2,455	3,154

Borrowings are counted again inside the liabilities due within a year and after a year.

Cash flow

Consolidated, ₹ crore, years to March.

₹ crore	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026Filed 15 May
	356	520	432	521	582	511
	394	520	530	661	723	662
	14	−5	−67	15	−77	−150
Receivables	18	−23	−63	−40	−93	−169
Inventories	6	−12	6	−7	−13	−33
Payables	24	2	−34	24	48	55
Other working capital	−34	29	24	38	−18	−4
Tax paid	−38	0	−95	−140	−141	−151
Capital spending	94	170	526	647	1,009	1,428
Free cash flow	262	350	−94	−126	−427	−917
	−354	−606	−616	−753	−1,116	−1,452
Plant and property sold	0	0	3	1	47	0
Companies bought	0	0	−216	−75	−178	0
Interest received	4	13	11	2	9	11
	10	60	88	217	543	940
Borrowings raised	91	124	389	531	878	1,539
Borrowings repaid	−141	−233	−241	−18	−84	−210
Interest paid	−27	−12	−19	−59	−123	0
Lease payments	0	0	−41	−56	−40	−74
Dividends paid	0	0	0	0	0	207
Shares bought back	95	0	0	0	0	0
Shares issued	0	192	0	0	0	49
Net change in cash	12	−26	−95	−15	9	−1

Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Consolidated, ₹ per share, years to March.

₹ per share	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026Filed 15 May
	₹5.37	₹8.38	₹8.41	₹7.75	₹9.61	₹6.03
As stated that year	₹26.87	₹41.88	₹42.03	₹38.75	₹9.61	₹6.03
	₹5.24	₹8.38	₹8.41	₹7.75	₹9.61	₹6.03
As stated that year	₹26.20	₹41.88	₹42.03	₹38.75	₹9.61	₹6.03
	–	₹34.67	₹41.72	₹45.69	₹53.45	₹56.19
On that year's share count	–	₹173.35	₹208.62	₹228.47	₹53.45	₹56.19
Shareholder yield	–	−1.7%	0.0%	0.0%	0.0%	0.6%
Market cap at the year end (₹ crore)	–	11,069	11,215	16,480	25,593	24,869

Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from.

Ratios

Consolidated, years to March.Krishna Institute of Medical Sciences PE ratio and valuation

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026Filed 15 May
Revenue growth	–	24.1%	33.1%	13.7%	21.5%	28.6%
Operating profit growth	–	39.1%	17.1%	6.0%	22.2%	2.4%
Net profit growth	–	67.3%	6.4%	−8.1%	23.4%	−41.7%
Earnings per share growth	–	55.9%	0.4%	−7.8%	24.0%	−37.3%
	23.3%	29.6%	22.0%	17.7%	19.4%	11.0%
	–	6.3 pts	−7.6 pts	−4.3 pts	1.7 pts	−8.4 pts
From the net margin	–	7.7 pts	−7.1 pts	−4.2 pts	0.4 pts	−9.9 pts
From asset turnover	–	2.1 pts	−1.8 pts	−3.4 pts	−2.5 pts	−0.8 pts
From borrowing	–	−3.5 pts	1.4 pts	3.3 pts	3.8 pts	2.4 pts
Return on capital employed	27.0%	28.2%	18.1%	14.3%	12.2%	8.9%
Cash conversion	173.2%	151.3%	118.1%	155.1%	140.3%	211.1%
Interest cover	9.3	27.6	15.5	10.5	6.7	2.6
Debt to equity	0.27	0.11	0.35	0.65	1.06	1.27
Receivable days	30	28	42	43	48	52
Inventory days	30	37	33	34	37	44
Payable days	167	133	132	136	157	146
Cash conversion cycle, days	−106	−67	−58	−59	−72	−50
Working capital days	−15	3	15	20	3	17
Asset turnover	0.93	0.99	0.91	0.74	0.63	0.58
Assets per rupee of net worth	1.66	1.49	1.59	1.94	2.42	3.08
Sales per rupee of plant	1.73	2.14	1.59	1.44	1.38	0.93
Capital spending to depreciation	1.36	2.34	4.07	4.42	5.69	5.04
Plant being built, % of plant in use	1.2%	2.7%	34.5%	34.7%	55.2%	14.5%

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year: 3.6%
Cash from operations against operating profit: 63.7%

Measure	5 years	3 years
Revenue growth, yearly rate	24.0%	21.1%
Profit growth, yearly rate	3.7%	−10.5%
Return on equity, average	19.9%	16.0%
Return on capital employed, average	16.4%	11.8%
Operating margin, average	26.1%	24.0%
Net margin, average	14.2%	11.1%
Asset turnover, average	0.77	0.65
Cash conversion cycle, days, average	−61	−60
Interest cover, average	12.6	6.6
Debt to equity, average	0.69	0.99

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore	5 years	3 years	Latest year
Cash from operations	2,566	1,614	511
Cash from investing	−4,543	−3,320	−1,452
Cash from financing	1,848	1,700	940
Capital spending	3,780	3,084	1,428
Dividends paid	207	207	207
Shares bought back	0	0	0
Shares issued for cash	240	49	49
Borrowings raised	3,460	2,947	1,539
Borrowings repaid	785	311	210

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

Check	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9	–	–	5	5	5	5
Altman Z-scorePublished threshold 1.81	–	16.11	8.86	7.38	6.00	3.94
Beneish M-scorePublished threshold −1.78	–	−2.44	−1.80	−2.69	−2.29	−2.42
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets	–	25.73	22.66	16.71	19.80	17.53
Cash from operations to profit, 3 yearsPublished threshold 0.7 times	–	–	1.43	1.41	1.37	1.63
Receivables growth less revenue growthOur threshold 0 percentage points	–	−6.99	63.28	2.85	12.81	11.51
Inventory growth less cost-of-goods growthOur threshold 0 percentage points	–	28.32	−17.66	5.02	11.22	22.37
Other current assets growth less revenue growthOur threshold 5 per cent of revenue	–	0.47	0.44	2.77	−0.94	0.92
Assets under construction, years of additionsOur threshold 2 years of additions	–	0.29	0.65	1.21	1.88	0.27
Effective tax ratePublished threshold 17.16 per cent	26.36	25.56	24.56	26.88	25.68	27.74
Tax charged less tax paid, % of profitOur threshold 10 percentage points	–	25.56	4.88	−3.59	0.34	−17.84

A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

Date	Agency	Borrowing rated	Rating	Outlook	Amount, ₹ Cr
29 Jun 2026	CRISIL Ratings Limited	Bank Facilities	Crisil A1+Review, Re-affirm		37.50
29 Jun 2026	CRISIL Ratings Limited	Bank Facilities	Crisil AAReview, Re-affirm	Stable	75
12 Jan 2026	CARE Ratings Limited	Non-fund-based - LT/ ST-BG/LC	CARE AA / CARE A1+New, New	Stable	3.60
12 Jan 2026	CARE Ratings Limited	Fund-based - LT-Term Loan	CARE AANew, New	Stable	801.40
12 Jan 2026	CARE Ratings Limited	Fund-based - LT/ ST-Working Capital Limits	CARE AA / CARE A1+New, New	Stable	345

The latest rating on each borrowing. The agency's name opens its reasoning for the rating.